ClinicalTrials.gg
Not yet recruitingNCT05824065GENERAUpdated Feb 16, 2024

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

A Phase 3 interventional study of OMA102 and OMA102 in Female Pattern Baldness, sponsored by EMS. Not yet recruiting at 1 site in Brazil. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by EMS · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Alopecia with a site in Brazil — 8 open to participants now, 8 under way, 5 of them phase 3. Alopecia · Brazil.

Planned enrollment
Largest of 14
504 · median 133
Started
2025
the only one that year
Phase 3
7 of 14
5 open now
Registered
5th of 14
by date
Lead sponsor
2 of 14
EMS

Among the 14 studies in Alopecia with a site in Brazil, this one has the largest planned enrollment, is the only one that started in 2025, is one of 7 in phase 3, and was the 5th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

8 of the 14 studies in Alopecia with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Alopecia with a site in Brazil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.

03

Conditions studied

  • Female Pattern Baldness

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the forms;
  • Age greater than 18 and equal or under 50 years;
  • Confirmed diagnosis of female pattern hair loss, grade II to IV in Sinclair Scale;
  • Participants that are disposed to maintain the same hair color, style, approximate hair length throughout the Clinical Study.

Exclusion criteria

Exclusion Criteria:

  • Any clinical or physical finding interpreted by the investigator as a risk to subject participation in the Clinical Study
  • History of alcohol or illicit drugs abuse in the last year;
  • Pregnant or breastfeeding women, who are planning to become pregnant or participants who have and are not using any reliable method;
  • Allergy or sensibility to any knowing components of the formula;
  • Diagnosis of arterial hypertension;
  • History of vasovagal syncope;
  • Baseline systolic blood pressure lower than 90 mmHg and/or diastolic lower than 60 mmHg;
  • Diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmHg and/or diastolic equal or superior to 10 mmHg after 3 minutes in orthostatic position);
  • (BMI) > 30 kg/m²;
  • Subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the Clinical Study;
  • History of cardiovascular, liver and renal diseases;
  • History of hypothyroidism, hyperthyroidism or pheochromocytoma;
  • Signs or symptoms of cardiopathy or angina;
  • History of edema from any etiology;
  • Participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, or monoamine oxidase inhibitors;
  • Use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months;
  • Dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss;
  • History of surgical treatment for hair loss or presence of shaved scalp;
  • Scalp microinfusion, microneedling or intradermotherapy in the last 3 years;
  • Vaginal or cesarean deliveries 6 months before the inclusion in the study;
  • Drastic modification of habitual diet, as food restrictions or hyperselectivity;
  • Current cancer or history of cancer in the last 5 years;
  • Participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
504 participants (estimated)

Study arms

  • Experimental
    OMA102 1 mg

    Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep

    Drug: OMA102

  • Experimental
    OMA102 2 mg

    Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep

    Drug: OMA102

  • Placebo comparator
    Placebo

    Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep

    Drug: Placebo

Interventions

  • DrugOMA102

    1 mg

  • DrugOMA102

    2 mg

  • DrugPlacebo

    OMA102 - Placebo

06

What researchers measure

Primary outcomes

  1. Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.

    Variation of hair in the mid-front area after 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.

    Time frame: 6 months

Secondary outcomes

  1. Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.

    Variation of hair in the mid-front area after 3 months of treatment in comparison to baseline, assessed by digital phototrichogram.

    Time frame: 3 months

  2. Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of non vellus and vellus hair growth, in the mid frontal area, assessed by digital phototrichogram.

    Variation of non vellus and vellus hair in the mid-front area after 3 and 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.

    Time frame: 3 and 6 months

  3. Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception.

    Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement global photographs assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception, 3 and 6 months after treatment.

    Time frame: 3 and 6 months

  4. Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Patient Global Impression, PGI-I, by the subject perception.

    Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of Global Photographs assessed by Patient Global Impression PGI-I, by the investigator perception, 3 and 6 months after treatment.

    Time frame: 3 and 6 months

  5. Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL).

    Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL) in comparison to baseline, 3 and 6 months after treatment.

    Time frame: 3 and 6 months

07

Study locations

1 site
  • EMS
    Hortolândia, São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Apr 21, 2023
StartEst.
Jan 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05824065
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Jan 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 16, 2024

Study contacts

Cassiano Ricardo O Berto, B.S.
Contact
pesquisa.clinica@ncfarma.com.br
+551938877724

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion